Recently Viewed
empty-cart

There are no Recent Items

Close
Login/Register

Close
Single User License Price USD 2000
Single User License Price INR 134900
Corporate User License Price USD 6000
Corporate User License Price INR 404700
Site License Price USD 4000
Site License Price INR 269800
Request a Quote

Report Title

Klebsiella pneumoniae Infections-Pipeline Review, H1 2017

Quote Request for License Type
License Type Price  
Single User License USD 2000
Site License USD 4000
Enterprise Wide License USD 6000
"Thanks for submitting the form. Our marketing team will connect back to you for the budget constraint."
Close
REQUEST A CUSTOMIZED RESEARCH

Report Title

Klebsiella pneumoniae Infections-Pipeline Review, H1 2017


Quote Request for License Type
License Type Price  
Single User License USD 2000
"Thanks for letting us know your requirement. Our research team will connect back to you for the bespoke requirement."
Close
REQUEST FOR SAMPLE REPORT

Report Title

Klebsiella pneumoniae Infections-Pipeline Review, H1 2017

"Thanks for submitting the form. The concerned team will send the sample report in the next 12 hours."
"Thank you for downloading the sample report."
Close

Klebsiella pneumoniae Infections-Pipeline Review, H1 2017



Executive Summary

Klebsiella pneumoniae Infections-Pipeline Review, H1 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Klebsiella pneumoniae Infections-Pipeline Review, H1 2017, provides an overview of the Klebsiella pneumoniae Infections (Infectious Disease) pipeline landscape.

Klebsiella pneumoniae is a Gram-negative bacteria. A Klebsiella pneumoniae infection is caused when the organism is able to enter the lungs. A Klebsiella pneumoniae infection is very common in patients with underlying diseases like diabetes, chronic lung diseases and chronic alcoholics. It is mostly a nosocomial infection that occurs in hospitalized patients with weakened immune system. Symptoms include necrosis, inflammation, hemorrhage, chills, dizziness, high fever, head ache and chest pain. Treatment includes antibiotics and hygiene lifestyle.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Klebsiella pneumoniae Infections-Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Klebsiella pneumoniae Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Klebsiella pneumoniae Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Klebsiella pneumoniae Infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase I, Preclinical and Discovery stages are 1, 1, 19 and 8 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 2 and 3 molecules, respectively.

Klebsiella pneumoniae Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

The pipeline guide provides a snapshot of the global therapeutic landscape of Klebsiella pneumoniae Infections (Infectious Disease).

The pipeline guide reviews pipeline therapeutics for Klebsiella pneumoniae Infections (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Klebsiella pneumoniae Infections (Infectious Disease) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Klebsiella pneumoniae Infections (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Klebsiella pneumoniae Infections (Infectious Disease)

Reasons to buy

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Klebsiella pneumoniae Infections (Infectious Disease).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Klebsiella pneumoniae Infections (Infectious Disease) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Klebsiella pneumoniae Infections-Overview

Klebsiella pneumoniae Infections-Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Klebsiella pneumoniae Infections-Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Klebsiella pneumoniae Infections-Companies Involved in Therapeutics Development

Appili Therapeutics

Cellceutix Corp

Debiopharm International SA

Evaxion Biotech ApS

F. Hoffmann-La Roche Ltd

FOB Synthesis Inc

ImmunoClin Corp

Kyorin Pharmaceutical Co Ltd

Melinta Therapeutics Inc

Nosopharm SAS

Peptilogics Inc

Pfizer Inc

Phico Therapeutics Ltd

Sarepta Therapeutics Inc

Shionogi & Co Ltd

Soligenix Inc

Syntiron LLC

Tetraphase Pharmaceuticals Inc

Klebsiella pneumoniae Infections-Drug Profiles

Antisense Oligonucleotide to Inhibit NDM-1 for Klebsiella Pneumoniae Infections-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ASN-300-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ATI-1503-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CA-824-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CC-1807-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

cefiderocol-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Debio-1454-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

dusquetide-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

EBX-004-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

FSI-1671-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

FSI-1686-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GNeg Snare-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

IBN-1-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

interleukin-22-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Klebsiella pneumoniae vaccine-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Klebsiella pneumoniae vaccine-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Klebsiella pneumoniae vaccine-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

mirandamycin-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NOSO-95179-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Onc-72-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

OTP-602-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Peptides for Infectious Diseases-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PT-4-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RX-05-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RXP-873-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit Lipopolysaccharide for Nosocomial Infections-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit LpxC for Gram-Negative Bacterial Infections-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules for Bacterial and Fungal Infections-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules for Bacterial Infections-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules for Bacterial Infections-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules for Klebsiella pneumoniae Infections-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules for Multi-Drug Resistant Gram-Positive and Gram-Negative Bacterial Infections-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TP-6076-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

WLBU-2-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Klebsiella pneumoniae Infections-Dormant Projects

Klebsiella pneumoniae Infections-Discontinued Products

Klebsiella pneumoniae Infections-Product Development Milestones

Featured News & Press Releases

Apr 20, 2017: Arsanis Presents Data on ASN-300 at the 27th European Congress of Clinical Microbiology and Infectious Diseases

Apr 11, 2017: Appili Therapeutics Receives Funding from the Government of Canada to Support Development of New Antibiotic To Treat Gram-Negative Infections

Jun 17, 2016: Arsanis Presents Data at ASM Microbe 2016 Demonstrating Protection Against Klebsiella pneumoniae using Monoclonal Antibody Technology

Mar 09, 2015: Phico Therapeutics Receives Translation Award to Advance its SASPject PT4 Aimed at Escherichia coli and Klebsiella pneumoniae Towards Clinical Trials

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

To know more information on Purchase by Section, please send a mail to sales@kenresearch.com

List of Figures

Number of Products under Development for Klebsiella pneumoniae Infections, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Number of Products by Top 10 Targets, H1 2017

Number of Products by Stage and Top 10 Targets, H1 2017

Number of Products by Top 10 Mechanism of Actions, H1 2017

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017

Number of Products by Routes of Administration, H1 2017

Number of Products by Stage and Routes of Administration, H1 2017

Number of Products by Top 10 Molecule Types, H1 2017

Number of Products by Stage and Top 10 Molecule Types, H1 2017

List of Tables

Number of Products under Development for Klebsiella pneumoniae Infections, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Products under Development by Companies, H1 2017

Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Products under Development by Universities/Institutes, H1 2017

Number of Products by Stage and Target, H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017

Number of Products by Stage and Route of Administration, H1 2017

Number of Products by Stage and Molecule Type, H1 2017

Klebsiella pneumoniae Infections-Pipeline by Appili Therapeutics, H1 2017

Klebsiella pneumoniae Infections-Pipeline by Cellceutix Corp, H1 2017

Klebsiella pneumoniae Infections-Pipeline by Debiopharm International SA, H1 2017

Klebsiella pneumoniae Infections-Pipeline by Evaxion Biotech ApS, H1 2017

Klebsiella pneumoniae Infections-Pipeline by F. Hoffmann-La Roche Ltd, H1 2017

Klebsiella pneumoniae Infections-Pipeline by FOB Synthesis Inc, H1 2017

Klebsiella pneumoniae Infections-Pipeline by ImmunoClin Corp, H1 2017

Klebsiella pneumoniae Infections-Pipeline by Kyorin Pharmaceutical Co Ltd, H1 2017

Klebsiella pneumoniae Infections-Pipeline by Melinta Therapeutics Inc, H1 2017

Klebsiella pneumoniae Infections-Pipeline by Nosopharm SAS, H1 2017

Klebsiella pneumoniae Infections-Pipeline by Peptilogics Inc, H1 2017

Klebsiella pneumoniae Infections-Pipeline by Pfizer Inc, H1 2017

Klebsiella pneumoniae Infections-Pipeline by Phico Therapeutics Ltd, H1 2017

Klebsiella pneumoniae Infections-Pipeline by Sarepta Therapeutics Inc, H1 2017

Klebsiella pneumoniae Infections-Pipeline by Shionogi & Co Ltd, H1 2017

Klebsiella pneumoniae Infections-Pipeline by Soligenix Inc, H1 2017

Klebsiella pneumoniae Infections-Pipeline by Syntiron LLC, H1 2017

Klebsiella pneumoniae Infections-Pipeline by Tetraphase Pharmaceuticals Inc, H1 2017

Klebsiella pneumoniae Infections-Dormant Projects, H1 2017

Klebsiella pneumoniae Infections-Dormant Projects, H1 2017 (Contd..1), H1 2017

Klebsiella pneumoniae Infections-Discontinued Products, H1 2017

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Appili Therapeutics, Cellceutix Corp, Debiopharm International SA, Evaxion Biotech ApS, F. Hoffmann-La Roche Ltd, FOB Synthesis Inc, ImmunoClin Corp, Kyorin Pharmaceutical Co Ltd, Melinta Therapeutics Inc, Nosopharm SAS, Peptilogics Inc, Pfizer Inc, Phico Therapeutics Ltd, Sarepta Therapeutics Inc, Shionogi & Co Ltd, Soligenix Inc, Syntiron LLC, Tetraphase Pharmaceuticals Inc

Klebsiella pneumoniae Infections Therapeutic Products under Development, Key Players in Klebsiella pneumoniae Infections Therapeutics, Klebsiella pneumoniae Infections Pipeline Overview, Klebsiella pneumoniae Infections Pipeline, Klebsiella pneumoniae Infections Pipeline Assessment


Related Products in vertical
red-whiteline

RECENT VIEWED REPORTS



Sign up for newsletter

Close
Apply For Job

  • Applicant Name
  • Job Function
  • Total Experience
  • Skills
  • Email ID
  • Notice Period
  • Current CTC & Expected CTC
  • Phone Number
  • Validation
  • captcha  info-icon

    If validation code does not match, please refresh the page.

  • "Your resume has been successfully received. HR will connect you within 14 days in case your resume gets shortlisted."
Close
Download Company Brochure

  • Name
  • Email
  • Company Name
  • Select Country*
  • Phone Number
  • Validation
  •   info-icon

    If validation code does not match, please refresh the page.

Close
Engage With Us

  • Name
  • Designation
  • Email
  • Phone No.
  • Company Name
  • Company URL
  • Select Country*
  • Requirements/ Comments
  • Validation
  • captcha  info-icon

    If validation code does not match, please refresh the page.

  • "Thanks for submitting the form. The concerned team will respond to your query in the next 8-12 hours"
Close

Compare

Expand